News

SeqLL Provides First Quarter 2022 Financial Results and a Corporate Update

BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company…

2 years ago

Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update

Nyxol Posts 5 Positive Clinical Data Readouts Including Presbyopia in Last 12 Months Successfully Enrolled 4 Late-Stage Trials for Nyxol…

2 years ago

MEDIROM Healthcare Technologies Inc. Announces Preliminary 2021 Financial Results

Revenue growth of 62% / Total Gross Margin 26.4%NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc.…

2 years ago

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering…

2 years ago

Vitalhub Corp to Present at the Roth Canada Showcase Day

TORONTO, May 13, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) today announces that will be…

2 years ago

Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products

Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disordersFORT COLLINS, Colo., May 13, 2022…

2 years ago

LifeMD, Inc. Reports First Quarter 2022 Results

First quarter 2022 consolidated revenue of $29.0 million up 60% from the same year ago period.Adjusted EPS of $(0.25), 14%…

2 years ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update

Expands rare cannabinoid portfolio with the addition of CBT and CBDVStrengthens IP with publication of a patent application for novel…

2 years ago

BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years

-Entered into a definitive agreement to sell the rare pediatric disease Priority Review Voucher (PRV) it obtained in February 2021…

2 years ago

Spectral Announces First Quarter Results and Provides Corporate Update

TORONTO, May 13, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic…

2 years ago